NCT06045286View on ClinicalTrials.gov

High- and Low-dose Radiotherapy Combined With PD-1 Inhibitors for MSS CRLM

PHASE1RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

September 20, 2023

Primary Completion Date

September 30, 2024

Study Completion Date

December 31, 2025

Conditions
Colorectal Liver Metastases
Interventions
RADIATION

Radiation: High- and Low-dose radiotherapy

High-dose radiotherapy (6-8Gy×3-7F) followed by low-dose radiotherapy (0.5-1.4Gy×3-7F) starting within 7 days after completion.

DRUG

PD-1 Inhibitors

Immunotherapy (Zimberelimab) is given every three weeks within one week after the end of high-dose radiotherapy.

Trial Locations (1)

210009

RECRUITING

Jiangsu Cancer Hospital, Nanjing

All Listed Sponsors
lead

Jiangsu Cancer Institute & Hospital

OTHER